Q/C TECHNOLOGIES, INC.
Close on Oct 19, 2026
- Market cap
- $4.12M
- P/E (TTM)
- –
- Dividend yield
- –
About Q/C Technologies
In Vitro & In Vivo Diagnostic Substances, SIC 2835
Q/C Technologies, Inc. is a corporate registrant with operations structured across reporting segments, including Pharmaceuticals and Computing Technology. The company engages in specialized commercial initiatives within these defined operating areas. Its business structure is supported by multiple classes of equity instruments and preferred stock series, along with contractual consulting arrangements and corporate equity incentive plans.
The company maintains its principal executive offices in New York, New York, located at 1185 Avenue of the Americas. Its operational records reflect property leases and related facilities, including lease agreements and locations associated with Baltimore. Additionally, the company is incorporated in the State of Delaware and conducts its primary activities under domestic state and federal jurisdictions within the United States.
Summary of the business section of Q/C Technologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Q/C TECHNOLOGIES, INC.
- Founded
- 2014
- Headquarters
- New York, NY
- Address
- 1185 Avenue Of The Americas, Suite 249 10036
- Phone
- (856) 848-8698
- Employees
- 2, Dec 31, 2025
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Stephano Slack LLC, Wayne, Pennsylvania
Stock & identifiers
- Ticker
- QCLS
- Exchange
- Nasdaq
- IPO date
- Jan 23, 2014
- Shares outstanding
- 8M, Aug 12, 2026
- Public float
- $3.62M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-97 reverse, Nov 19, 2025; 1-for-100 reverse, Sep 2, 2025; 1-for-30 reverse, Feb 15, 2024; 1-for-2 reverse, Apr 19, 2021; 1-for-22.5 reverse, Mar 25, 2020; 1-for-24 reverse, Nov 25, 2019; 1-for-8 reverse, Nov 14, 2018; 1-for-8 reverse, Nov 8, 2018
- SEC CIK
- 1321834
- CUSIP
- 62856X300
- ISIN
- US62856X3008
- LEI
- 213800CSKAC96ELS4K25
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joshua Silverman | Executive Chairman, Director | 262,191 |
| Mitchell Glass | Chief Medical Officer, Director | 12,500 |
| Yossef Ehrlichman | Chief Technology Officer | – |
| Charles Todd Fagan | Chief Financial Officer | – |
| Ian Thomas Rhodes | Interim CFO | – |
| Chelsea Sierra Voss | Director | 301,455 |
| Stephen Friscia | Director | 25,000 |
| Billy Joe White | Director | 25,024 |
| Bruce Bernstein | Director | 25,023 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Former Peo | $420.23K | -$1.10M | $120.07K | $29 | – |
| FY2024 Non Peo Neo | – | $188.33K | $120.07K | $29 | – |
| FY2024 Peo | $175.83K | $175.83K | $120.07K | $29 | – |
| FY2023 Non Peo Neo | – | -$6.12M | $444.76K | $195 | – |
| FY2023 Peo | $2.88M | -$6.40M | $444.76K | $195 | – |
| FY2022 Non Peo Neo | – | -$4.52M | $234.66K | $29 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, the Company had two full-time employees and no part-time employees.”
Corporate history
Events identified from SEC filings